Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature currently requires accessing the site using the built-in Safari browser.
Normal
One blindside from the FDA not enough to open up your eyes? Here is a second non-approval from today. Analysts had rated Biomarin as a stock to buy based on the favorable profile of their treatment.Glad you know what the FDA will do for Acadiahttps://www.barrons.com/articles/biomarin-stock-valrox-fda-rejection-hemophilia-gene-therapy-51597853794
One blindside from the FDA not enough to open up your eyes? Here is a second non-approval from today. Analysts had rated Biomarin as a stock to buy based on the favorable profile of their treatment.
Glad you know what the FDA will do for Acadia
https://www.barrons.com/articles/biomarin-stock-valrox-fda-rejection-hemophilia-gene-therapy-51597853794
